|
Market Closed -
Euronext Paris
11:55:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 0.3000 EUR | -6.25% |
|
-18.92% | -99.66% |
| 06-30 | Neovacs bolsters its strategic intellectual property portfolio |  |
| 02-10 | Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEOVACS | Other Biotechnology & Medical Research | -6.25% | -18.92% | -99.66% | -99.99% | -100.00% | 55.38K |  | | |
- Stock Market
- Stocks
- ALNEV Stock
- Charts NEOVACS
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
